Investors

August 7, 2018

Novelion Therapeutics Reports Second Quarter 2018 Financial Results

In This Section

Breadcrumb

Home // Investors //

Investors

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Copyright West LLC. Minimum 15 minutes delayed.